Skip to main content

Table 6 Antiplatelet prescription in patients already using OAC classified by HAS-BLED score

From: Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand’s COOL-AF registry

  Total patients Non-antiplatelet HAS-BLED score p
  0–2 3 or more
All CAD, n (%) 408 353 55  
 No antiplatelet 222 (54.4%) 196 (55.5%) 26 (47.3%) 0.253
 Single antiplatelet 153 (37.5%) 128 (36.3%) 25 (45.5%) 0.190
 Dual antiplatelets 33 (8.1%) 29 (8.2%) 4 (7.3%) 1.000
DES < 1 year, n (%) 27 23 4  
 No antiplatelet 3 (11.1%) 3 (13.0%) 0 (0.0%) 1.000
 Single antiplatelet 7 (25.9%) 6 (26.1%) 1 (25.0%) 1.000
 Dual antiplatelets 17 (63.0%) 14 (60.9%) 3 (75.0%) 1.000
DES > 1 year or BMS for any duration, n (%) 125 108 17  
 No antiplatelet 41 (32.8%) 35 (32.4%) 6 (35.3%) 0.814
 Single antiplatelet 73 (58.4%) 63 (58.3%) 10 (58.8%) 0.970
 Dual antiplatelets 11 (8.8%) 10 (9.3%) 1 (5.9%) 1.000
History of ACS within 1 year, n (%) 42 33 9  
 No antiplatelet 21 (50.0%) 17 (51.5%) 4 (44.4%) 1.000
 Single antiplatelet 12 (28.6%) 9 (27.3%) 3 (33.3%) 0.699
 Dual antiplatelets 9 (21.4%) 7 (21.2%) 2 (22.2%) 1.000
CAD without prior ACS or PCI, n (%) 386 332 54  
 No antiplatelet   189 (56.9%) 26 (48.1%) 0.102
 Single antiplatelet   115 (34.6%) 25 (46.3%) 0.053
 Dual antiplatelets   28 (8.4%) 3 (5.6%) 1.000
  1. A p-value < 0.05 indicates statistical significance
  2. OAC, oral anticoagulant; HAS-BLED, Hypertension, Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly, Drug/alcohol usage; CAD, coronary artery disease; DES, drug-eluting stent; BMS, bare-metal stent; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention